Head-to-head comparison of 68 Ga-FAPI-46 PET/CT, 18F-FDG PET/CT, and contrast-enhanced CT for the detection of various tumors
Masao Watanabe(Essen University Hospital), Manuel Weber(Essen University Hospital), Stefan Kasper(Essen University Hospital), Hong Grafe(Essen University Hospital), Bastian von Tresckow(University of Cologne), David Kersting(West German Heart and Vascular Center Essen), Kim M. Pabst(Klinik und Poliklinik für Nuklearmedizin), Wolfgang P. Fendler(Essen University Hospital), Helena Lanzafame(Düsseldorf University Hospital), Fadi Zarrad(Essen University Hospital), Martin Stuschke(Essen University Hospital), Jens T. Siveke(German Cancer Research Center), Céline Lugnier(Ruhr University Bochum), Hubertus Hautzel(Deutsches Konsortium für Translationale Krebsforschung), Nader Hirmas(Deutsches Konsortium für Translationale Krebsforschung), Boris Hadaschik(Essen University Hospital), Rainer Hamacher(Technical University of Munich), Clemens Aigner(Essen University Hospital), Viktor Grünwald(Essen University Hospital), Sherko Kümmel(Kliniken Essen-Mitte), Ken Herrmann(Klinikum rechts der Isar)
Cited by 15
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial
|The Lancet Oncology|2007|808
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523
Metabolic Imaging Predicts Response, Survival, and Recurrence in Adenocarcinomas of the Esophagogastric Junction
|Journal of Clinical Oncology|2006|464